CG Oncology, Inc. (CGON)
NASDAQ: CGON · Real-Time Price · USD
26.31
-0.38 (-1.42%)
At close: Aug 1, 2025, 4:00 PM
26.51
+0.20 (0.76%)
After-hours: Aug 1, 2025, 4:33 PM EDT
CG Oncology Revenue
CG Oncology had revenue of $52.00K in the quarter ending March 31, 2025, a decrease of -90.17%. This brings the company's revenue in the last twelve months to $662.00K, up 224.51% year-over-year. In the year 2024, CG Oncology had annual revenue of $1.14M with 458.33% growth.
Revenue (ttm)
$662.00K
Revenue Growth
+224.51%
P/S Ratio
3,029.44
Revenue / Employee
$5,858
Employees
113
Market Cap
2.01B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.14M | 935.00K | 458.33% |
| Dec 31, 2023 | 204.00K | 13.00K | 6.81% |
| Dec 31, 2022 | 191.00K | -10.17M | -98.16% |
| Dec 31, 2021 | 10.36M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionCGON News
- 5 weeks ago - CG Oncology: Looking Undervalued Heading Toward FDA Submission (Upgrade) - Seeking Alpha
- 2 months ago - CG Oncology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewsWire
- 2 months ago - CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates - GlobeNewsWire
- 3 months ago - CG Oncology's Bladder Cancer Drug Impresses Investors - Here's Why - Benzinga
- 3 months ago - CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting - GlobeNewsWire
- 4 months ago - CG Oncology Looks Attractive At Current Prices (Rating Upgrade) - Seeking Alpha
- 4 months ago - Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy - GlobeNewsWire
- 5 months ago - CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference - GlobeNewsWire